// App-Quantinova.ai

BSH2020‐PO‐144 : C3 inhibition with pegcetacoplan in the treatment of subjects with paroxysmal nocturnal hemoglobinuria

Researchers

Presenter

  • C. de Castro

Principal Investigators

  • F. Grossi

  • J. Maciejewski

  • I. Weitz

  • V. Sharma

  • E. Roman

  • R. Brodsky

  • L. Tan

  • D. El Mehdi

  • P. Deschatelets

  • C. Francois

Medical Centers

  • Duke University College of Medicine, Durham, NC

  • Apellis Pharmaceuticals, Waltham, MA

  • Taussig Cancer Institute/Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

  • UCLA School of Medicine, Los Angeles, CA

  • The University of Louisville, Louisville, KY

  • Lakes Research, Miami Lakes, FL

  • Johns Hopkins Oncology Center, Baltimore, MD, USA

  • Lisa Tan Pharma Consulting Limited, Cambridge, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Venous thrombosis

  • Anemia

Biomarkers

  • Complement Factor B

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Prospective

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02264639

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved